Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)

被引：1

作者：

Chan, S. L. ^{[1
]}

Sangro, B. ^{[2
,3
]}

Kelley, R. K. ^{[4
]}

Lau, G. ^{[5
]}

Kudo, M. ^{[6
]}

Sukeepaisarnjaroen, W. ^{[7
]}

De Toni, E. N. ^{[8
]}

Furuse, J. ^{[9
]}

Kang, Y-K. ^{[10
]}

Galle, P. R. ^{[11
]}

Rimassa, L. ^{[12
]}

Heurgue, A. ^{[13
]}

Tam, V. C. ^{[14
]}

Dao, T. V. ^{[15
]}

Thungappa, S. Chiradoni ^{[16
]}

Breder, V. ^{[17
]}

Ostapenko, Y. V. ^{[18
]}

Reig Monzon, M. E. ^{[19
]}

Gupta, C. ^{[20
]}

Abou-Alfa, G. K. ^{[21
,22
]}

机构：

[1] Chinese Univ Hong Kong, Dept Clin Oncol, Sir Yue Kong Pao Ctr Canc, State Key Lab Translat Oncol, Hong Kong, Peoples R China

[2] Univ Navarra Clin, Liver Unit & HPB Oncol Area, Pamplona, Spain

[3] CIBEREHD, Pamplona, Spain

[4] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[5] Humanity & Hlth Med Grp, Humanity & Hlth Clin Trial Ctr, Hong Kong, Peoples R China

[6] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan

[7] Khon Kaen Univ, Songklanagarind Hosp, Dept Med, Khon Kaen, Thailand

[8] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med II, Munich, Germany

[9] Kanagawa Canc Ctr, Dept Gastroenterol, Yokohama, Kanagawa, Japan

[10] Univ Ulsan, Coll Med, Dept Oncol, Seoul, South Korea

[11] Univ Med Ctr, Dept Internal Med I, Mainz, Germany

[12] Humanitas Univ, IRCCS Humanitas Res Hosp, Pieve Emanuele & Humanitas Canc Ctr, Dept Biomed Sci, Milan, Italy

[13] Robert Debre Hosp, Det Hepatogastroenterol, Reims, France

[14] Univ Calgary, Tom Baker Canc Ctr, Dept Oncol, Calgary, AB, Canada

[15] Natl Canc Hosp, Canc Res & Clin Trials Ctr, Dept Optimal Therapy, Hanoi, Vietnam

[16] Hlth Care Global Enterprises Ltd, Med Oncol Dept, Bangalore, Karnataka, India

[17] NN Blokhin Russian Canc Res Ctr, Chemotherapy Unit, Moscow, Russia

[18] Natl Canc Inst, Intervent Radiol, Dept Minimally Invas & Endoscop Surg, Kiev, Ukraine

[19] Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, Liver Unit,Barcelona Clinic Liver Canc BCLC, Barcelona, Spain

[20] AstraZeneca, Oncol Biometr, Wilmington, DE USA

[21] Cornell Univ, Mem Sloan Kettering Canc, Dept Med, New York, NY USA

[22] Cornell Univ, Weill Med Coll, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.282

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

147P

引用

页码：S1530 / S1531

页数：2

共 50 条

[1] Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Sangro, B.
Chan, S. L.
Kelley, R. K.
Lau, G.
Kudo, M.
Sukeepaisarnjaroen, W.
Yarchoan, M.
De Toni, E. N.
Furuse, J.
Kang, Y. K.
Galle, P. R.
Rimassa, L.
Heurgue, A.
Tam, V. C.
Van Dao, T.
Thungappa, S. C.
Breder, V.
Ostapenko, Y.
Reig, M.
Makowsky, M.
Paskow, M. J.
Gupta, C.
Kurland, J. F.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2024, 35 (05) : 448 - 457
[2] FOUR-YEAR OVERALL SURVIVAL UPDATE FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB PLUS DURVALUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
Abou-Alfa, Ghassan K.
Chan, Stephen Lam
Kelley, Kate
Lau, George
Kudo, Masatoshi
Sukeepaisarnjaroen, Wattana
De Toni, Enrico N.
Furuse, Junji
Kang, Yoon Koo
Galle, Peter R.
Rimassa, Lorenza
Heurgue, Alexandra
Tam, Vincent C.
Tu Van Dao
Thungappa, Satheesh Chiradoni
Breder, Valeriy
Ostapenko, Yuriy
Reig, Maria
Makowsky, Mallory
Gupta, Charu
Negro, Alejandra
Sangro, Bruno
[J]. HEPATOLOGY, 2023, 78 : S90 - S91
[3] Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Sangro, B.
Chan, S.
Kelley, R.
Lau, G.
Kudo, M.
Sukeepaisarnjaroen, W.
De Toni, E.
Furuse, J.
Kang, Y.
Galle, P.
Rimassa, L.
Heurgue, A.
Tam, V.
Dao, T.
Thungappa, S.
Breder, V.
Ostapenko, Y.
Reig, M.
Makowsky, M.
Gupta, C.
Negro, A.
Abou-Alfa, G.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S168 - S168
[4] Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Chan, L. S.
Kudo, M.
Sangro, B.
Kelley, R. K.
Furuse, J.
Park, J-W.
Sunpaweravong, P.
Fasolo, A.
Yau, T.
Kawaoka, T.
Cheng, A-L.
Azevedo, S.
Reig Monzon, M. E.
Assenat, E.
Yarchoan, M.
He, A. R.
Makowsky, M.
Ran, D.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S869 - S870
[5] Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Chan, S. L.
Kudo, M.
Sangro, B.
Kelley, R. K.
Furuse, J.
Park, J-W.
Sunpaweravong, P.
Fasolo, A.
Yau, T.
Kawaoka, T.
Cheng, A-L.
Azevedo, S.
Reig Monzon, M. E.
Assenat, E.
Yarchoan, M.
He, A. R.
Makowsky, M.
Gupta, C.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S1456 - S1456
[6] Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Chan, S. L.
Kudo, M.
Sangro, B.
Kelley, R. K.
Furuse, J.
Park, J-W.
Sunpaweravong, P.
Fasolo, A.
Yau, T.
Kawaoka, T.
Cheng, A-L.
Azevedo, S.
Reig Monzon, M. E.
Assenat, E.
Yarchoan, M.
He, A. R.
Makowsky, M.
Gupta, C.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S1456 - S1456
[7] Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Chan, S. L.
Kudo, M.
Sangro, B.
Kelley, R. K.
Furuse, J.
Park, J-W.
Sunpaweravong, P.
Fasolo, A.
Yau, T.
Kawaoka, T.
Cheng, A-L.
Azevedo, S.
Reig Monzon, M. E.
Assenat, E.
Yarchoan, M.
He, A. R.
Makowsky, M.
Ran, D.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S1465 - S1466
[8] Outcomes by comorbidities (CMs) with tremelimumab (T) and durvalumab (D) in the phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
Rimassa, L.
Dayyani, F.
Kelley, R. K.
Sangro, B.
Chan, S. L.
Mccoy, C. L.
Paskow, M. J.
Makowsky, M.
Gupta, C.
Ran, D.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2024, 35 : S77 - S78
[9] Non-viral aetiology subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Monzon, M. E. Reig
Tam, V. C.
Sangro, B.
Archambeaud, I.
Kelley, R. K.
Chan, S. L.
Kudo, M.
Masi, G.
Paskow, M. J.
Makowsky, M.
Gupta, C.
Ran, D.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2024, 35 : S75 - S76
[10] Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
Sangro, Bruno
Galle, Peter R.
Kelley, Robin Kate
Charoentum, Chaiyut
De Toni, Enrico N.
Ostapenko, Yurii
Heo, Jeong
Cheng, Ann-Lii
Woods, Andrea Wilson
Gupta, Charu
Abraham, Jayne
Mccoy, Carrie L.
Patel, Nikunj
Negro, Alejandra
Vogel, Arndt
Abou-Alfa, Ghassan K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23)

← 1 2 3 4 5 →